

# **ERSTE STOCK BIOTEC**

**Jointly owned fund pursuant to the InvFG**

Semi-Annual Report 2023

## Contents

General Information about the Investment Firm .....	3
Asset Allocation .....	4
Statement of Assets and Liabilities as of 14 September 2023 .....	5

## General Information about the Investment Firm

<b>The company</b>	Erste Asset Management GmbH Am Belvedere 1, A-1100 Vienna Telephone: +43 05 0100-19777, fax: +43 05 0100-919777
<b>Registered capital</b>	EUR 2.50 million
<b>Shareholders</b>	Erste Group Bank AG (64.67%) Erste Bank der österreichischen Sparkassen AG (22.17%) Steiermärkische Bank und Sparkassen Aktiengesellschaft (3.30%) Tiroler Sparkasse Bankaktiengesellschaft Innsbruck (1.74%) DekaBank Deutsche Girozentrale, Frankfurt (1.65%) „Die Kärntner“ Trust-Vermögensverwaltungsgesellschaft m. b. H. & Co KG (1.65%) Salzburger Sparkasse Bank Aktiengesellschaft (1.65%) Sieben Tiroler Sparkassen Beteiligungsgesellschaft m. b. H. (1.65%) NÖ-Sparkassen Beteiligungsgesellschaft m. b. H. (0.76%) VIENNA INSURANCE GROUP AG Wiener Versicherung Gruppe (0.76%)
<b>Supervisory Board</b>	Rudolf SAGMEISTER (Chairman) Manfred BARTALSZKY Maximilian CLARY UND ALDRINGEN Harald GASSER Gerhard GRABNER Harald Frank GRUBER Oswald HUBER (Deputy Chairman) Radovan JELASITY Ertan PISKIN Peter PROBER Gabriele SEMMELROCK-WERZER Reinhard WALT Gerald WEBER Appointed by the Works Council: Martin CECH Regina HABERHAUER Heinrich Hubert REINER Peter RIEDERER Nicole WEINHENGST Manfred ZOUREK
<b>Managing directors</b>	Heinz BEDNAR Winfried BUCHBAUER Peter KARL Thomas KRAUS
<b>Prokuristen (proxies)</b>	Karl FREUDENSCHUSS Manfred LENTNER (until 31.08.2023) Günther MANDL Gerold PERMOSER Magdalena REISCHL Oliver RÖDER Magdalena UJWARY (from 16.08.2023)
<b>State commissioners</b>	Wolfgang EXL Angelika SCHÄTZ
<b>Auditor</b>	Ernst & Young Wirtschaftsprüfungsgesellschaft m.b.H.
<b>Depositary bank</b>	Erste Group Bank AG

## Dear Unit-holder,

We are pleased to present you the following semi-annual report for the ERSTE STOCK BIOTEC jointly owned fund pursuant to the InvFG for the period from 15 March 2023 to 14 September 2023.

## Asset Allocation

	As of 14.09.2023	
	EUR millions	%
Equities		
EUR	3.3	1.41
USD	226.9	97.64
Transferable securities	230.2	99.05
Bank balances	2.3	0.97
Dividend entitlements	0.1	0.06
Interest entitlements	0.0	0.01
Other deferred items	-0.2	-0.10
Fund assets	232.4	100.00

# Statement of Assets and Liabilities as of 14 September 2023

(including changes in securities assets from 15 March 2023 to 14 September 2023)

Security designation	ISIN number	Purch./ additions	Sales/ disposals	Holding Units/nominal (nom. in 1,000, rounded)	Price	Value in EUR	% share of fund assets
<b>Publicly traded securities</b>							
<b>Equities denominated in USD</b>							
<b>Issue country USA</b>							
2SEVENTY BIO INC.DL-.0001	US9013841070	0	0	4,999	3.620	16,967.21	0.01
89BIO INC. DL-.001	US2825591033	53,000	0	53,000	17.730	881,055.74	0.38
ALLOGENE THERAP. DL-.001	US0197701065	0	0	31,400	3.950	116,290.84	0.05
ARCUTIS BIOTHER. DL-.0001	US03969K1088	0	0	11,100	6.780	70,562.09	0.03
BEAM THERAPEUTICS DL-.01	US07373V1052	0	0	21,700	25.140	511,497.82	0.22
CARIBOU BIOSCI. DL-.0001	US1420381089	0	0	13,900	5.650	73,634.62	0.03
DAY ONE BIOPHARMAC.-.0001	US23954D1090	0	0	51,200	14.640	702,796.87	0.30
HARMONY BIOSC.HLD.-.00001	US4131971040	0	0	13,100	38.030	467,107.03	0.20
KARUNA THERAPEUT.DL-.0001	US48576A1007	0	0	7,070	182.320	1,208,571.94	0.52
KEROS THERAPEUTICS -.0001	US4923271013	0	0	5,700	35.150	187,853.36	0.08
KYMERA THERAP.INC. -.0001	US5015751044	0	0	27,000	19.380	490,609.91	0.21
LYELL IMMUNOPH. DL-.0001	US55083R1041	0	0	54,000	1.745	88,350.29	0.04
NKARTA INC. DL -.0001	US65487U1088	0	0	7,200	1.640	11,071.21	0.00
PASSAGE BIO INC. DL-.0001	US7027121000	0	0	55,800	0.751	39,290.98	0.02
RECURSION PHARM.A -.00001	US75629V1044	0	0	33,500	8.600	270,123.29	0.12
RELAY THERAP. DL-.001	US75943R1023	0	0	23,100	9.610	208,139.33	0.09
SANA BIOTECHNO. DL -.0001	US7995661045	0	0	40,000	4.505	168,955.98	0.07
SEER INC. CL.A N.P.	US81578P1066	0	0	13,000	2.570	31,325.30	0.01
SPRINGWOR.TH.INC.DL-.0001	US85205L1070	0	0	12,300	26.870	309,878.58	0.13
VERVE THERAPEUTICS -.001	US92539P1012	0	0	11,300	12.910	136,780.27	0.06
VIR BIOTECHN.INC.DL-.0001	US92764N1028	0	0	28,800	10.040	271,109.65	0.12
ZENTALIS PHARMAC. DL-.001	US98943L1070	0	0	9,800	23.790	218,594.53	0.09
Total issue country USA						<u>6,480,566.84</u>	<u>2.79</u>
<b>Issue country British Virgin Islands</b>							
BIOHAVEN LTD	VGG1110E1079	17,000	0	27,900	19.410	507,748.35	0.22
Total issue country British Virgin Islands						<u>507,748.35</u>	<u>0.22</u>
Total equities denominated in USD translated at a rate of 1.06655						<u>6,988,315.19</u>	<u>3.01</u>
Total publicly traded securities						<u>6,988,315.19</u>	<u>3.01</u>
<b>Securities admitted to organised markets</b>							
<b>Equities denominated in EUR</b>							
<b>Issue country France</b>							
SANOFI SA BEARER EO 2	FR0000120578	0	0	32,000	102.420	3,277,440.00	1.41
Total issue country France						<u>3,277,440.00</u>	<u>1.41</u>
Total equities denominated in EUR						<u>3,277,440.00</u>	<u>1.41</u>

# ERSTE STOCK BIOTEC

Security designation	ISIN number	Purch./ additions Units/nominal (nom. in 1,000, rounded)	Sales/ disposals	Holding	Price	Value in EUR	% share of fund assets
<b>Equities denominated in USD</b>							
<b>Issue country Bermuda</b>							
ROIVANT SCIENCES	BMG762791017	182,000	0	182,000	11.490	1,960,695.70	0.84
Total issue country Bermuda						<u>1,960,695.70</u>	<u>0.84</u>
<b>Issue country Cayman Islands</b>							
BEIGENE LTD SP.ADR	US07725L1026	0	0	12,600	198.500	2,345,037.74	1.01
LEGEND BIOTECH SP.ADS/2	US52490G1022	0	0	9,700	65.110	592,158.83	0.25
MEIRAGTX HLDGSDL-.0000388	KYG596651029	0	0	21,200	5.680	112,902.35	0.05
ZAI LAB LTD ADR/10	US98887Q1040	0	0	15,100	25.580	362,156.49	0.16
Total issue country Cayman Islands						<u>3,412,255.41</u>	<u>1.47</u>
<b>Issue country Denmark</b>							
ASCENDIS PH.SP.ADR 1 DK 1	US04351P1012	0	0	18,500	103.390	1,793,366.46	0.77
GENMAB AS SP.ADR/1/10DK 1	US3723032062	0	0	12,000	38.530	433,509.92	0.19
Total issue country Denmark						<u>2,226,876.38</u>	<u>0.96</u>
<b>Issue country Great Britain</b>							
ASTRAZENECA DL-.25 SP.ADR	US0463531089	0	0	163,648	67.780	10,399,945.09	4.48
AUTOLUS THERAP. SP.ADR/1	US05280R1005	0	0	195,000	2.890	528,385.92	0.23
BICYCLE THERAP. SP.ADR/1	US0887861088	0	0	14,000	20.910	274,473.77	0.12
ROYALTY PHARMA OA DL-0001	GB00BMVP7Y09	0	0	97,000	28.760	2,615,648.59	1.13
Total issue country Great Britain						<u>13,818,453.37</u>	<u>5.95</u>
<b>Issue country Ireland</b>							
HORIZON THERAP.PLC DL-.01	IE00BQPQZ61	0	2,600	106,100	115.350	11,474,975.39	4.94
JAZZ PHARMACEUT. DL-.0001	IE00B4Q5ZN47	0	0	13,500	133.820	1,693,844.64	0.73
PROTHENA CORP. PLC DL-.01	IE00B91XRN20	0	0	10,200	54.170	518,057.29	0.22
Total issue country Ireland						<u>13,686,877.32</u>	<u>5.89</u>
<b>Issue country Canada</b>							
ABCELLERA BIOLOGICS	CA00288U1066	0	0	62,000	5.170	300,539.12	0.13
XENON PHARMACEUTICALS	CA98420N1050	0	0	35,000	36.680	1,203,694.15	0.52
Total issue country Canada						<u>1,504,233.27</u>	<u>0.65</u>
<b>Issue country Netherlands</b>							
ARGENS SE SP.ADR/1 -.10	US04016X1019	8,000	0	16,800	523.380	8,244,136.70	3.55
MERUS N.V. EO -.09	NL0011606264	0	0	9,400	24.950	219,895.93	0.09
UNIQUIRE N.V. EO -.05	NL0010696654	0	0	41,300	7.660	296,618.07	0.13
Total issue country Netherlands						<u>8,760,650.70</u>	<u>3.77</u>

Security designation	ISIN number	Purch./ additions Units/nominal (nom. in 1,000, rounded)	Sales/ disposals	Holding	Price	Value in EUR	% share of fund assets
<b>Issue country Switzerland</b>							
CRISPR THERAPEUT. SF -.03	CH0334081137	0	0	16,700	51.280	802,940.32	0.35
Total issue country Switzerland						802,940.32	0.35
<b>Issue country Spain</b>							
GRIFOLS SP.ADR B EO-.10 1	US3984384087	0	0	27,056	9.860	250,126.26	0.11
Total issue country Spain						250,126.26	0.11
<b>Issue country USA</b>							
ACADIA PHARMACEUT. DL-.01	US0042251084	42,000	0	132,600	25.850	3,213,829.64	1.38
AD.BIOTECH.CORP. DL-.0001	US00650F1093	0	0	35,700	6.210	207,863.67	0.09
AGIOS PHARMACEUT. DL-.001	US00847X1046	0	0	51,200	26.880	1,290,381.14	0.56
ALECTOR INC.	US0144421072	0	0	19,000	6.370	113,478.04	0.05
ALNYLAM PHARMACE.DL-.0001	US02043Q1076	0	0	28,510	193.060	5,160,696.26	2.22
AMGEN INC. DL-.0001	US0311621009	0	23,000	50,300	262.300	12,370,437.39	5.32
AMICUS THERAPEUTICS INC.	US03152W1099	0	0	116,850	13.110	1,436,316.63	0.62
ANAVEX LIFE SCI. DL-.001	US0327973006	0	0	18,000	7.950	134,170.92	0.06
APELLIS PHARMACEUT.DL-.0001	US03753U1060	36,000	51,650	24,000	43.310	974,581.59	0.42
ARROWHEAD PHARMAC. DL-.01	US04280A1007	0	0	33,200	30.540	950,661.48	0.41
AXSOME THERAPEUT. DL-0001	US05464T1043	0	0	11,000	76.200	785,898.46	0.34
BIOCRIST PHARMAC. DL-.01	US09058V1035	0	0	40,000	6.920	259,528.39	0.11
BIOGEN INC. DL -.0005	US09062X1037	0	0	51,200	256.320	12,304,705.83	5.30
BIOMARIN PHAR. DL-.001	US09061G1013	0	0	59,100	87.680	4,858,551.40	2.09
BLUEPRINT MED.CORP.DL-001	US09627Y1091	0	0	25,100	51.370	1,208,932.54	0.52
BRIDGEBIO PHARMA DL-.001	US10806X1028	0	0	68,225	29.620	1,894,730.20	0.82
CYTOKINETICS INC. DL-.001	US23282W6057	0	0	18,450	34.210	591,790.82	0.25
DENALI THERAP.INC. DL-.01	US24823R1059	0	0	26,900	24.170	609,603.86	0.26
EDITAS MEDICINE DL-.0001	US28106W1036	0	0	15,000	8.400	118,137.92	0.05
ENANTA PHARMA.INC. DL-.01	US29251M1062	0	0	24,500	13.230	303,909.80	0.13
EXACT SCIEN. DL-.01	US30063P1057	0	0	40,500	77.380	2,938,343.26	1.26
EXELIXIS INC. DL-.01	US30161Q1040	0	0	74,500	22.270	1,555,590.46	0.67
GILEAD SCIENCES DL-.001	US3755581036	0	0	249,200	77.360	18,075,206.98	7.78
GUARDANT HEALTH CL. A	US40131M1099	0	0	82,600	30.760	2,382,238.06	1.03
HALOZYME THERAPEU.DL-.001	US40637H1095	0	0	47,800	40.520	1,816,001.13	0.78
ILLUMINA INC. DL-.01	US4523271090	0	0	32,300	150.490	4,557,523.79	1.96
IMMUNOGEN INC. DL-.01	US45253H1014	0	0	47,000	15.760	694,500.96	0.30
INCYTE DL-.001	US45337C1027	0	0	51,200	63.480	3,047,373.31	1.31
INHIBRX INC. DL -.0001	US45720L1070	0	0	8,700	20.000	163,142.84	0.07
INSMED INC. DL-.01	US4576693075	0	0	47,600	26.670	1,190,278.94	0.51
INTELLIA THERAPEU DL-.01	US45826J1051	0	0	22,100	36.010	746,163.80	0.32
INTRA-CELLUL.THE.DL-.0001	US46116X1019	0	0	23,400	56.390	1,237,190.94	0.53
IONIS PHARMACEUT. DL-001	US4622221004	0	0	51,300	43.640	2,099,040.83	0.90
IOVANCE BIOTHERAP.DL-.001	US4622601007	0	0	34,000	4.645	148,075.57	0.06
KODIAK SCIENCES DL-.0001	US50015M1099	0	0	11,300	2.210	23,414.75	0.01
KRYSTAL BIOTECH DL-.00001	US5011471027	0	0	5,400	119.000	602,503.40	0.26
KURA ONCOLOGY DL-.0001	US50127T1097	0	0	11,000	9.700	100,042.19	0.04
LIGAND PHARMAC.NEW DL-001	US53220K5048	0	0	4,300	62.290	251,134.03	0.11
MADRIGAL PHARMAC. DL-.01	US5588681057	0	0	11,000	175.340	1,808,391.54	0.78

## ERSTE STOCK BIOTEC

Security designation	ISIN number	Purch./ additions Units/nominal (nom. in 1,000, rounded)	Sales/ disposals	Holding	Price	Value in EUR	% share of fund assets
MARAVAI LIFESC.HLD.A -.01	US56600D1072	0	0	28,400	10.330	275,066.34	0.12
MEDPACE HOLDINGS DL-.01	US58506Q1094	0	0	8,450	280.030	2,218,605.32	0.95
MIRATI THERAPEUTICS DL-01	US60468T1051	0	0	25,200	33.040	780,655.38	0.34
MIRUM PHARMAC. DL-.0001	US6047491013	30,000	0	30,000	32.360	910,224.56	0.39
MODERNA INC. DL-.0001	US60770K1079	0	0	57,800	112.810	6,113,560.55	2.63
MORPHIC HOLDING IDL-.0001	US61775R1059	0	0	8,500	55.120	439,285.55	0.19
NANOSTR.TECHNOL. DL-.0001	US63009R1095	0	0	9,900	1.860	17,265.01	0.01
NEKTAR THERAPEUTICS	US6402681083	0	0	46,800	0.667	29,250.27	0.01
NEUROCRINE BIOSCI. DL-001	US64125C1099	0	0	23,800	113.780	2,538,993.95	1.09
OCULAR THERAPEUT.DL-.0001	US67576A1007	0	0	158,800	3.610	537,497.54	0.23
PACIRA BIOSCIENC. DL-.001	US6951271005	0	0	9,800	34.770	319,484.32	0.14
PTC THERAPEUTICS DL-.001	US69366J2006	0	0	48,600	37.390	1,703,768.22	0.73
REATA PHARMA INC. 0.001	US75615P1030	0	0	23,000	172.060	3,710,449.58	1.60
REGENERON PHARMAC.DL-.001	US75886F1075	0	2,700	22,000	832.380	17,169,715.44	7.39
REGENXBIO INC. DL-.0001	US75901B1070	0	0	13,000	18.080	220,374.10	0.09
REPLIMUNE GR. INC DL-.001	US76029N1063	0	0	11,900	18.510	206,524.78	0.09
REVOLUTION MED. DL-.0001	US76155X1000	0	0	17,400	32.550	531,029.96	0.23
ROCKET PHARMAT. DL-.01	US77313F1066	0	0	16,700	24.050	376,574.00	0.16
SAGE THERAPEUTICS DL-0001	US78667J1088	0	0	28,500	21.490	574,248.75	0.25
SANGAMO THERAP.INC.DL-.01	US8006771062	0	0	38,000	1.000	35,628.90	0.02
SAREPTA THERAP. DL-.0001	US8036071004	0	0	41,400	119.720	4,647,140.78	2.00
SEAGEN INC. DL-.001	US81181C1045	0	0	50,450	206.500	9,767,873.05	4.20
SELECTA BIOSCI. DL -.0001	US8162121045	0	0	107,000	1.160	116,375.23	0.05
ULTRAGENYX PHARM. DL-.001	US90400D1081	0	0	15,010	39.260	552,522.24	0.24
UTD THERAP. (DEL.) DL-.01	US91307C1027	0	0	16,600	219.490	3,416,186.77	1.47
VAXCYTE INC. DL -.001	US92243G1085	0	0	29,000	51.500	1,400,309.41	0.60
VERACYTE INC. DL-.001	US92337F1075	0	0	17,000	25.210	401,828.32	0.17
VERTEX PHARMAC. DL-.01	US92532F1003	0	5,000	61,520	349.415	20,154,714.55	8.67
VOYAGER THERAP. DL -.001	US92915B1061	0	0	188,900	8.210	1,454,098.73	0.63
XENCOR INC. DL-.01	US98401F1057	0	0	32,200	20.930	631,893.49	0.27
Total issue country USA						173,475,507.85	74.66
Total equities denominated in USD translated at a rate of 1.06655						219,898,616.58	94.64
Total securities admitted to organised markets						223,176,056.58	96.05

### Unlisted securities

#### Equities denominated in USD

##### Issue country USA

ADURO BIOTECH INC. CONTRA	QOXDBM073949	0	0	21,400	0.000	0.00	0.00
OMNIAB A(USD15 VESTING)	US68218J3014	1,631	0	1,631	0.000	0.00	0.00
OMNIAB(12.50 VES.)DL-.001	US68218J2024	1,631	0	1,631	0.000	0.00	0.00
RADIUS HEALTH INC.DL-0001 km	QOXDBM079862	0	0	15,000	0.000	0.00	0.00
Total issue country USA						0.00	0.00
Total equities denominated in USD translated at a rate of 1.06655						0.00	0.00
Total unlisted securities						0.00	0.00



**Breakdown of fund assets**

Transferable securities	230,164,371.77	99.05
Bank balances	2,259,212.56	0.97
Dividend entitlements	140,856.03	0.06
Interest entitlements	26,492.21	0.01
Other deferred items	-226,325.54	-0.10
<b>Fund assets</b>	<b>232,364,607.03</b>	<b>100.00</b>

**Investor note:**

**The values of assets in illiquid markets may deviate from their actual selling prices.**

Dividend-bearing units outstanding	AT0000746748	units	80,365.297
Value of dividend-bearing unit	AT0000746748	EUR	455.06
Dividend-bearing units outstanding	AT0000A1YFC3	units	0.000
Value of dividend-bearing unit	AT0000A1YFC3	EUR	113.48
Non-dividend-bearing units outstanding	AT0000746755	units	286,897.815
Value of non-dividend-bearing unit	AT0000746755	EUR	455.04
Non-dividend-bearing units outstanding	AT0000A1YFD1	units	0.000
Value of non-dividend-bearing unit	AT0000A1YFD1	EUR	112.58
KEST-exempt non-dividend-bearing units outstanding	AT0000673165	units	22,733.311
Value of KEST-exempt non-dividend-bearing unit	AT0000673165	EUR	498.44
KEST-exempt non-dividend-bearing units outstanding	AT0000A0XYPO	units	95,988.125
Value of KEST-exempt non-dividend-bearing unit	AT0000A0XYPO	CZK	12,227.21
KEST-exempt non-dividend-bearing units outstanding	AT0000A18XC5	units	11,994.711
Value of KEST-exempt non-dividend-bearing unit	AT0000A18XC5	HUF	191,371.25
KEST-exempt non-dividend-bearing units outstanding	AT0000A1YFE9	units	0.000
Value of KEST-exempt non-dividend-bearing unit	AT0000A1YFE9	EUR	115.64
KEST-exempt non-dividend-bearing units outstanding	AT0000A1YFG4	units	0.000
Value of KEST-exempt non-dividend-bearing unit	AT0000A1YFG4	CZK	2,792.92
KEST-exempt non-dividend-bearing units outstanding	AT0000A1YFF6	units	713.624
Value of KEST-exempt non-dividend-bearing unit	AT0000A1YFF6	HUF	45,387.61

The Fund is not permitted to engage in repurchase agreements pursuant to Regulation (EU) No. 2015/2365 (Regulation on Transparency of Securities Financing Transactions and of Reuse). For this reason, repurchase agreements were not employed.

No total return swaps pursuant to Regulation (EU) 2015/2365 (Regulation on Transparency of Securities Financing Transactions and of Reuse) were concluded for the Fund during the reporting period.

The Fund is not permitted to engage in securities lending agreements pursuant to Regulation (EU) No. 2015/2365 (Regulation on Transparency of Securities Financing Transactions and of Reuse). For this reason, securities lending agreements were not employed.

**Explanation on disclosure pursuant to Delegated Regulation (EU) No. 2016/2251 supplementing Regulation (EU) No. 648/2012 of the European Parliament and of the Council on OTC derivatives, central counterparties, and trade repositories with regard to regulatory technical standards for risk-mitigation techniques for OTC derivative contracts not cleared by a central counterparty:**

All OTC derivatives are traded through Erste Group Bank AG.

In the event of negative derivatives exposure, collateral in the form of cash or bonds is pledged to Erste Group Bank AG in accordance with the contractually agreed threshold.

In the event of positive derivatives exposure, EUR-denominated bonds from the national governments or central banks of the countries of the Eurozone are pledged by Erste Group Bank AG to the Fund in accordance with the contractually agreed threshold. A one-time discount of 4% is agreed with the counterparty for this collateral. In the event of regulatory requirements that stipulate a different discount or the provision of alternative collateral, these requirements are met.

**Purchases and sales of transferable securities in the reporting period not listed in the statement of assets and liabilities**

Security designation	ISIN number	Purch./ additions Units/nominal (nom. in 1,000, rounded)	Sales/ disposals
<b>Publicly traded securities</b>			
<b>Equities denominated in USD</b>			
<b>Issue country USA</b>			
AVIDITY BIOSC.INC.-.0001	US05370A1088	0	10,900
C4 THERAPEUTICS DL-.0001	US12529R1077	0	10,700
ERASCA INC. DL -.0001	US29479A1088	0	25,000
GRAPHITE BIO INC. -.00001	US38870X1046	0	11,900
INSTIL BIO INC.DL-.000001	US45783C1018	0	27,500
IVERIC BIO INC. DL-.001	US46583P1021	0	66,300
PROMETHEUS BIOSC.DL-.0001	US74349U1088	0	8,800

<b>Security designation</b>	<b>ISIN number</b>	<b>Purch./ additions Units/nominal (nom. in 1,000, rounded)</b>	<b>Sales/ disposals</b>
<b>Securities admitted to organised markets</b>			
<b>Equities denominated in USD</b>			
<b>Issue country Netherlands</b>			
ATAI LIFE SCIENCES BV EO1	NL0015000DX5	0	38,500
<b>Issue country USA</b>			
ATARA BIOTHERAP. DL-.0001	US0465131078	0	22,000
CHIMERIX INC. DL -.001	US16934W1062	0	121,000
CODEXIS INC. DL-.01	US1920051067	0	15,500
FATE THERAPEUTICS DL-.001	US31189P1021	0	30,700
HOMOLOGY MED. DL-.0001	US4380831077	0	57,500
KEZAR LIFE SCIENC.DL-.001	US49372L1008	0	31,000
PAC.BIOSCI.OF CAL.DL-.001	US69404D1081	0	98,500
SYNEOS HEALTH A DL-.01	US87166B1026	0	22,900
<b>Unlisted securities</b>			
<b>Equities denominated in USD</b>			
<b>Issue country USA</b>			
LIGAND PHARMACEUTICALS INC.	QOXDBM080878	0	1,630
LIGAND PHARMACEUTICALS INC.	QOXDBM080886	0	1,630

Vienna, September 2023

Erste Asset Management GmbH  
Electronically signed

Inspection information: The electronic signatures of this document can be inspected at the website of Rundfunk und Telekom Regulierungs-GmbH (<https://www.signatur.rtr.at/de/vd/Pruefung.html>).

Note: This document was signed with two qualified electronic signatures. A qualified electronic signature has the same legal effect as a hand-written signature (Article 25 of Regulation [EU] No 910/2014 [eIDAS Regulation]).